Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Integration of Precision Medicine Into Cancer Therapeutics, Part 2: A Therapeutic Phase 2 Sub-study Evaluating Genomic Testing in Human Cancer and Outcomes of Targeted Therapies Recommended by an Institutional Multidisciplinary Molecular Tumor Board in Patients With Poor Prognosis Cancer

NCT03089554 is registered in ClinicalTrials.gov with Rachel Miller as lead sponsor.

NCT NCT03089554
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03089554 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Integration of Precision Medicine Into Cancer Therapeutics, Part 2: A Therapeutic Phase 2 Sub-study Evaluating Genomic Testing in Human Cancer and Outcomes of Targeted Therapies Recommended by an Institutional Multidisciplinary Molecular Tumor Board in Patients With Poor Prognosis Cancer
Lead sponsor
Rachel Miller
Phase
Phase 2
Overall status
Recruiting
Start date
April 11, 2017
Completion date
April 30, 2027
Enrollment
93 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cancer